» Articles » PMID: 32063235

Apathy Predicts Rate of Cognitive Decline over 24 Months in Premanifest Huntington's Disease

Overview
Journal Psychol Med
Specialty Psychology
Date 2020 Feb 18
PMID 32063235
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cognitive impairment is a core feature of Huntington's disease (HD), however, the onset and rate of cognitive decline is highly variable. Apathy is the most common neuropsychiatric symptom of HD, and is associated with cognitive impairment. The aim of this study was to investigate apathy as a predictor of subsequent cognitive decline over 2 years in premanifest and early HD, using a prospective, longitudinal design.

Methods: A total of 118 premanifest HD gene carriers, 111 early HD and 118 healthy control participants from the multi-centre TRACK-HD study were included. Apathy symptoms were assessed at baseline using the apathy severity rating from the Short Problem Behaviours Assessment. A composite of 12 outcome measures from nine cognitive tasks was used to assess cognitive function at baseline and after 24 months.

Results: In the premanifest group, after controlling for age, depression and motor signs, more apathy symptoms predicted faster cognitive decline over 2 years. In contrast, in the early HD group, more motor signs, but not apathy, predicted faster subsequent cognitive decline. In the control group, only older age predicted cognitive decline.

Conclusions: Our findings indicate that in premanifest HD, apathy is a harbinger for cognitive decline. In contrast, after motor onset, in early diagnosed HD, motor symptom severity more strongly predicts the rate of cognitive decline.

Citing Articles

Exploring apathy components and their relationship in cognitive decline: insights from a network cross-sectional study.

Sarti P, Varrasi S, Guerrera C, Platania G, Furneri G, Torre V BMC Psychol. 2025; 13(1):129.

PMID: 39962563 PMC: 11834197. DOI: 10.1186/s40359-024-02239-x.


Cognitive engagement may slow clinical progression and brain atrophy in Huntington's disease.

De Paepe A, Plana-Alcaide Y, Garcia-Gorro C, Rodriguez-Dechicha N, Vaquer I, Calopa M Sci Rep. 2024; 14(1):30156.

PMID: 39627260 PMC: 11614872. DOI: 10.1038/s41598-024-76680-8.


[Psychiatric symptoms of Huntington's disease].

Muhlback A, Hoffmann R, Pozzi N, Marziniak M, Brieger P, Dose M Nervenarzt. 2024; 95(9):871-884.

PMID: 39212681 PMC: 11374876. DOI: 10.1007/s00115-024-01728-z.


The effect of Huntington's disease on cognitive and physical motivation.

Atkins K, Andrews S, Stout J, Chong T Brain. 2024; 147(7):2449-2458.

PMID: 38266149 PMC: 11224606. DOI: 10.1093/brain/awae023.


Mild cognitive impairment in Huntington's disease: challenges and outlooks.

Jellinger K J Neural Transm (Vienna). 2024; 131(4):289-304.

PMID: 38265518 DOI: 10.1007/s00702-024-02744-8.